Home|Journals|Articles by Year

Directory for Medical Articles

Review Article

AAM. 2013; 2(3): 99-103

Review on various experimental and clinical studies conducted on Makaradhwaja

Shraddha Nanasaheb Dhundi, Pradeep Kumar Prajapati.


Makaradhwaja a herbo-metalo-mineral formulation mainly composed of gold mercury and sulphur. It is a well known aphrodisiac, immune-modulator, rejuvenator, anti diabetic drug being used in many ailments viz. asthma, Koch’s disease, hyperpyrexia. Triguna Makaradhwaja had been prepared in 12 hrs and 18 hrs where as Shadaguna Makaradhwaja had been prepared in 36 hrs. Clinically Triguna and Shadaguna Makaradhwaja are proved anti diabetic. In experimental studies; no toxic effects on rabbits were found in therapeutic dose 3 mg/100 mg of body weight after administration for six weeks. For the safety index drug was given to albino rats in increasing order but up to 256 mg/kg body weight; no mortality was found. In the chronic toxicity study; no specific toxic effect had been indicated hence Makaradhwaja is safe for therapeutic purposes. Clinically the drug is having mild renoprotective effect. Dwiguna Makradwhaja administered in rabbits for the two weeks showed 3mg/ml/100g increase in force of contraction of ventricles indicating positive effect of Makaradhwaja on heart. Triguna Makaradhwaja is possessing anti diabetic and immune modulating activities. Inductively Coupled Plasma Optical Electron Spectroscopy (ICP OES) analysis revealed the presence of 7.2 ppm gold in Triguna Makaradhwaja whereas 663.1ppm in Shadguna Makaradhwaja prepared by Ashtasanskarita Parada. Both Triguna and Shadaguna Makaradhwaja offered Madhumehahar property (antidiabetic) on clinical trials but Shadguna Balijarita possess more than Triguna Balijarita Makaradhwaja.

Key words: Makaradhwaja, Antidiabetic, Rasayana, Chronic toxicity.

Full-text options

Share this Article

Online Article Submission
• ejmanager.com

Review(er)s Central
About BiblioMed
License Information
Terms & Conditions
Privacy Policy
Contact Us

The articles in Bibliomed are open access articles licensed under the terms of the Creative Commons Attribution-NonCommercial-ShareAlike 4.0 International License (https://creativecommons.org/licenses/by-nc-sa/4.0/) which permits unrestricted, non-commercial use, distribution and reproduction in any medium, provided the work is properly cited.